Orphan Drug Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Orphan Drug stocks.

Orphan Drug Stocks Recent News

Date Stock Title
May 21 GMAB Genmab Completes Acquisition of ProfoundBio
May 21 CNTA Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
May 17 IONS Ionis, Biogen Down on Ending Development of ALS Drug
May 17 CYTK Cytokinetics CEO Blum says positioned to market heart drug aficamten by itself
May 17 IONS Ionis (IONS), Biogen Down on Ending Development of ALS Drug
May 17 CYTK Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
May 16 IONS Biogen also drops collaboration with Ionis on Angelman syndrome candidate
May 16 IONS Biogen and Ionis drop ALS candidate after trial setback
May 16 IONS Biogen, Ionis shelve ALS drug following study failure
May 16 IONS REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
May 16 IONS Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16 IONS Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16 IONS Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
May 15 GMAB Market Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
May 15 RGEN Here’s Why Baron Discovery Fund Sold Repligen Corporation (RGEN)
May 15 CYTK Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
May 15 IONS Ionis to host 2024 virtual Annual Meeting of Stockholders
Orphan Drug

An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases.
The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy in many countries and has yielded medical breakthroughs that might not otherwise have been achieved, due to the economics of drug research and development.In the U.S. and the EU, it is easier to gain marketing approval for an orphan drug. There may be other financial incentives, such as an extended period of exclusivity, during which the producer has sole rights to market the drug. All are intended to encourage development of drugs which would otherwise lack sufficient profit motive to attract corporate research budgets and personnel.

Browse All Tags